ACB Fundamental Analysis - AURORA CANNABIS INC

Fundamental Rating

ACB gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 30 industry peers in the Pharmaceuticals industry. ACB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, ACB is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

ACB had negative earnings in the past year.

In the past year ACB had a positive cash flow from operations.

ACB had negative earnings in 4 of the past 5 years.

In the past 5 years ACB reported 4 times negative operating cash flow.

1.2 Ratios

ACB has a Return On Assets of -7.78%. This is comparable to the rest of the industry: ACB outperforms 47.06% of its industry peers.

ACB has a Return On Equity (-11.07%) which is in line with its industry peers.

		Industry Rank	Sector Rank
ROA	-7.78%
ROE	-11.07%
ROIC	N/A

ROA(3y)-55.32%

ROA(5y)-62.11%

ROE(3y)-90.28%

ROE(5y)-91.51%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ACB's Gross Margin of 1.69% is on the low side compared to the rest of the industry. ACB is outperformed by 79.41% of its industry peers.

In the last couple of years the Gross Margin of ACB has declined.

The Profit Margin and Operating Margin are not available for ACB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	1.69%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-29.39%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ACB does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for ACB has been increased compared to 1 year ago.

ACB has less shares outstanding than it did 5 years ago.

The debt/assets ratio for ACB has been reduced compared to a year ago.

2.2 Solvency

ACB has an Altman-Z score of -10.46. This is a bad value and indicates that ACB is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -10.46, ACB is doing worse than 88.24% of the companies in the same industry.

A Debt/Equity ratio of 0.07 indicates that ACB is not too dependend on debt financing.

Looking at the Debt to Equity ratio, with a value of 0.07, ACB is in the better half of the industry, outperforming 73.53% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	0.07
Debt/FCF	N/A
Altman-Z	-10.46

ROIC/WACCN/A

WACC8.56%

2.3 Liquidity

A Current Ratio of 3.41 indicates that ACB has no problem at all paying its short term obligations.

ACB's Current ratio of 3.41 is amongst the best of the industry. ACB outperforms 85.29% of its industry peers.

ACB has a Quick Ratio of 1.63. This is a normal value and indicates that ACB is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Quick ratio, with a value of 1.63, ACB is in the better half of the industry, outperforming 73.53% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.41
Quick Ratio	1.63

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 57.85% over the past year.

Looking at the last year, ACB shows a very strong growth in Revenue. The Revenue has grown by 23.87%.

The Revenue has been growing slightly by 6.94% on average over the past years.

EPS 1Y (TTM)57.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-4.55%

Revenue 1Y (TTM)23.87%

Revenue growth 3Y11.86%

Revenue growth 5Y6.94%

Sales Q2Q%11.4%

3.2 Future

ACB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 103.58% yearly.

ACB is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.91% yearly.

EPS Next Y-1574.6%

EPS Next 2Y178.87%

EPS Next 3Y73.82%

EPS Next 5Y103.58%

Revenue Next Year11.1%

Revenue Next 2Y9.83%

Revenue Next 3Y9.81%

Revenue Next 5Y7.91%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACB. In the last year negative earnings were reported.

The Price/Forward Earnings ratio is 16.12, which indicates a correct valuation of ACB.

Based on the Price/Forward Earnings ratio, ACB is valued a bit cheaper than the industry average as 70.59% of the companies are valued more expensively.

ACB is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 23.46, which is the current average of the S&P500 Index.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	16.12

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

ACB's earnings are expected to grow with 73.82% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y178.87%

EPS Next 3Y73.82%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ACB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

AURORA CANNABIS INC

TSX:ACB (12/24/2025, 7:00:00 PM)

6.27

-0.1 (-1.57%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)11-05 2025-11-05/bmo

Earnings (Next)02-03 2026-02-03/bmo

Inst Owners21.18%

Inst Owner ChangeN/A

Ins Owners0.04%

Ins Owner ChangeN/A

Market Cap352.50M

Revenue(TTM)367.13M

Net Income(TTM)-58.89M

Analysts73.33

Price Target8.08 (28.87%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-402.09%

Min EPS beat(2)-587.94%

Max EPS beat(2)-216.23%

EPS beat(4)1

Avg EPS beat(4)815.79%

Min EPS beat(4)-587.94%

Max EPS beat(4)4494.06%

EPS beat(8)2

Avg EPS beat(8)364.08%

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)1

Avg Revenue beat(2)0.81%

Min Revenue beat(2)-0.84%

Max Revenue beat(2)2.46%

Revenue beat(4)3

Avg Revenue beat(4)4.08%

Min Revenue beat(4)-0.84%

Max Revenue beat(4)13.79%

Revenue beat(8)6

Avg Revenue beat(8)4.16%

Revenue beat(12)8

Avg Revenue beat(12)3.93%

Revenue beat(16)9

Avg Revenue beat(16)2.81%

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)0%

EPS NQ rev (3m)15.91%

EPS NY rev (1m)-682.17%

EPS NY rev (3m)-682.17%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-0.27%

Revenue NY rev (1m)2.19%

Revenue NY rev (3m)2.19%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	16.12
P/S	0.96
P/FCF	N/A
P/OCF	157.16
P/B	0.66
P/tB	0.75
EV/EBITDA	N/A

EPS(TTM)-0.36

EYN/A

EPS(NY)0.39

Fwd EY6.2%

FCF(TTM)-0.33

FCFYN/A

OCF(TTM)0.04

OCFY0.64%

SpS6.53

BVpS9.46

TBVpS8.38

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-7.78%
ROE	-11.07%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	1.69%
FCFM	N/A

ROA(3y)-55.32%

ROA(5y)-62.11%

ROE(3y)-90.28%

ROE(5y)-91.51%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5Y-29.39%

F-Score5

Asset Turnover0.49

Health

		Industry Rank	Sector Rank
Debt/Equity	0.07
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	86.37%
Cap/Sales	5.6%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	3.41
Quick Ratio	1.63
Altman-Z	-10.46

F-Score5

WACC8.56%

ROIC/WACCN/A

Cap/Depr(3y)56.47%

Cap/Depr(5y)106.5%

Cap/Sales(3y)8.76%

Cap/Sales(5y)35.04%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)57.85%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-4.55%

EPS Next Y-1574.6%

EPS Next 2Y178.87%

EPS Next 3Y73.82%

EPS Next 5Y103.58%

Revenue 1Y (TTM)23.87%

Revenue growth 3Y11.86%

Revenue growth 5Y6.94%

Sales Q2Q%11.4%

Revenue Next Year11.1%

Revenue Next 2Y9.83%

Revenue Next 3Y9.81%

Revenue Next 5Y7.91%

EBIT growth 1Y-6.76%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year122.51%

EBIT Next 3Y30.92%

EBIT Next 5Y26.54%

FCF growth 1Y87.09%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y101.77%

OCF growth 3YN/A

OCF growth 5YN/A

AURORA CANNABIS INC / ACB.CA FAQ

Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ACB.CA.

Can you provide the valuation status for AURORA CANNABIS INC?

ChartMill assigns a valuation rating of 2 / 10 to AURORA CANNABIS INC (ACB.CA). This can be considered as Overvalued.

What is the profitability of ACB stock?

AURORA CANNABIS INC (ACB.CA) has a profitability rating of 1 / 10.

AURORA CANNABIS INC (ACB.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

AURORA CANNABIS INC / ACB.CA FAQ

Can you provide the ChartMill fundamental rating for AURORA CANNABIS INC?

Can you provide the valuation status for AURORA CANNABIS INC?

What is the profitability of ACB stock?